Related Experiment Video

Updated: Jun 8, 2026

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
09:53

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Published on: February 6, 2017

Steroid hormone receptors in cancer development: a target for cancer therapeutics

Nihal Ahmad1, Raj Kumar

  • 1Department of Dermatology, University of Wisconsin, Madison, WI, USA.

Cancer Letters
|October 8, 2010
PubMed

Insights

Steroid hormone receptors (SHRs) regulate genes involved in cancer development. Targeting SHRs and their coregulators offers promising endocrine-based therapies for various human malignancies.

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Oncology

Background:

  • Steroid hormone receptors (SHRs) are intracellular transcription factors crucial for cellular signaling.
  • SHRs mediate hormone responses by interacting with DNA and coregulatory proteins.
  • Dysregulation of SHR signaling is implicated in the development and progression of numerous cancers.

Purpose of the Study:

  • To review the current understanding of SHRs' role in cancer.
  • To explore the potential of endocrine-based therapies targeting SHRs and their coregulators.

Main Methods:

  • Literature review of studies on SHRs in cancer.
  • Analysis of SHR signaling pathways and their involvement in malignancies.
  • Evaluation of current and emerging therapeutic strategies targeting SHRs.

Main Results:

  • SHRs influence the development and growth of cancers like breast, prostate, and lung cancer.
  • Coregulators of SHRs play a significant role in cancer progression.
  • Hormonal therapies targeting SHRs have improved treatment outcomes, including reduced recurrence and increased survival rates.

Conclusions:

  • SHR signaling pathways are critical targets for novel cancer therapies.
  • Steroid receptor modulators offer a promising avenue for managing and treating various cancers.
  • Exploiting dysregulated SHR signaling in cancer provides a basis for effective, targeted endocrine-based treatments.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...